Kareem Ahmed Basha
Director & Chief Scientific Officer
- 11Articles written
- 7Areas of expertise
About Kareem
Kareem Ahmed Basha is a director and the chief scientific officer of Winhycare Pharma in Hyderabad, India. He writes and reviews the division’s technical content on peptides, peptide APIs and lyophilisation.
He has nearly two decades of experience in pharmaceutical quality control and quality assurance. His career includes 11 years 8 months at Dr. Reddy’s Laboratories, as Assistant Manager QA in Visakhapatnam, Quality Assurance Manager at the company’s site in Cuernavaca, Mexico, and most recently Team Leader, External Manufacturing Quality Assurance (EMQA) in Hyderabad, where his work included qualification audits of contract manufacturing organisations, quality agreements with manufacturing partners, and review of deviations, CAPA and change controls for technology transfer products.
Earlier he was Deputy Manager Quality Assurance at Anthem Biosciences in Bengaluru (2013 to 2014) and worked in quality control and quality assurance at Biocon in Bengaluru for six years (2007 to 2013).
Areas of expertise
- Pharmaceutical quality assurance (cGMP, GLP)
- Vendor qualification and CMO audits
- Deviations, CAPA and change control
- Data integrity and LIMS
- Technology transfer
- Peptide APIs
- Peptide lyophilisation
Articles by Kareem
Winhycare Pharma · Peptide APIs
CDMO vs CMO vs CRDMO: what is the difference, and which one does a pharma buyer need?
What CMO, CDMO and CRDMO mean in pharma, how their scope differs, what GMP rules apply to every contract manufacturer, and which model a buyer needs.
Kareem Ahmed Basha
Winhycare Pharma · Peptide APIs
Generic semaglutide: EU and US regulatory pathways, and what API makers must show
How generic semaglutide is filed in the EU and US: generic vs hybrid, 8+2+1 protection, ANDA vs 505(b)(2), synthetic vs recombinant API, API maker duties.
Kareem Ahmed Basha
Winhycare Pharma · Peptide APIs
How to qualify a peptide API supplier: a documentation and audit checklist for EU and US buyers
A documentation and audit checklist for qualifying a peptide API supplier for EU and US filings: written confirmation, DMF/ASMF, GMP audit, impurities and agreements.
Kareem Ahmed Basha
Winhycare Pharma · Peptide APIs
Lyophilised peptide stability and storage: how long a peptide API lasts and how to keep it
How long a lyophilised peptide API lasts, what degrades it, which storage temperatures ICH Q1A(R2) defines, how stability is tested and how to ship it safely.
Kareem Ahmed Basha
Winhycare Pharma · Peptide APIs
Peptide API impurities and specifications: thresholds, tests and what regulators expect in 2026
How peptide API impurities are classified and controlled: why ICH Q3A does not apply, Ph. Eur. 0.1/0.5/1.0% thresholds, FDA's 2026 peptide guidance and what a specification covers.
Kareem Ahmed Basha
Winhycare Pharma · Peptide APIs
Peptide lyophilisation: a practical guide to freeze-drying peptide APIs
How peptide freeze-drying works: freezing, primary and secondary drying, Tg′ and collapse temperature, excipients, cycle development and vial and stopper choices.
Kareem Ahmed Basha
Winhycare Pharma · Peptide APIs
How to read a semaglutide API certificate of analysis (COA)
A test-by-test guide to a semaglutide API COA: identity, assay, purity, peptide content, water, acetate, residual solvents, endotoxin and the specs behind them.
Kareem Ahmed Basha
Winhycare Pharma · Peptide APIs
Semaglutide patent expiry by country: dates, status and what it means for API buyers
When semaglutide's compound protection ends in India, China, Canada, Brazil, the US, EU, UK and Japan, with primary sources, and what it means for API buyers.
Kareem Ahmed Basha
Winhycare Pharma · Peptide APIs
Semaglutide vs tirzepatide vs liraglutide: how the three peptide APIs compare
How semaglutide, tirzepatide and liraglutide APIs differ: backbone, length, lipid chain, receptors, half-life basis, molecular weight, CAS and approval.
Kareem Ahmed Basha
Winhycare Pharma · Peptide APIs
SPPS vs LPPS vs hybrid: how peptide APIs are manufactured, and why the route matters to buyers
Solid-phase, liquid-phase and hybrid peptide synthesis compared for API buyers: chemistry, length limits, impurities, scale, solvent use and regulatory impact.
Kareem Ahmed Basha
Winhycare Pharma · Peptide APIs
What is a peptide API? API vs drug substance explained
A peptide API is the active ingredient of a peptide medicine. How ICH, FDA and EU law define API, drug substance and active substance, and where peptides fit.
Kareem Ahmed Basha